Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

A team of gene therapy veterans from the likes of Sangamo, Spark and AveXis have debuted Kriya with an untranched $80.5 million series A round to bring gene therapies to patients with prevalent and severe chronic diseases, starting with diabetes and obesity. To facilitate that goal, it’s focusing simultaneously on R&D and building infrastructure, including in-house manufacturing.

Founded in 2019, Kriya Therapeutics Inc. is starting with two preclinical adeno-associated virus (AAV) gene therapies licensed from Autonomous University of Barcelona (AUB): KT-A112 for Type I and II diabetes and KT-A832 for Type I diabetes; and one from NIH: KT-A522 for Type II diabetes and obesity. ...